A.R.T. Advisors LLC acquired a new stake in shares of Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 46,738 shares of the company’s stock, valued at approximately $1,203,000. A.R.T. Advisors LLC owned about 0.13% of Biohaven Pharmaceutical at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. BNP Paribas Arbitrage SA raised its holdings in Biohaven Pharmaceutical by 189.2% during the first quarter. BNP Paribas Arbitrage SA now owns 6,299 shares of the company’s stock valued at $162,000 after buying an additional 4,121 shares in the last quarter. DRW Securities LLC bought a new position in Biohaven Pharmaceutical during the first quarter valued at about $232,000. Endurant Capital Management LP bought a new position in Biohaven Pharmaceutical during the fourth quarter valued at about $278,000. State Board of Administration of Florida Retirement System bought a new position in Biohaven Pharmaceutical during the first quarter valued at about $329,000. Finally, Swiss National Bank bought a new position in Biohaven Pharmaceutical during the fourth quarter valued at about $413,000. Institutional investors own 77.29% of the company’s stock.
In other news, insider Robert Berman sold 104,155 shares of Biohaven Pharmaceutical stock in a transaction dated Tuesday, June 12th. The stock was sold at an average price of $36.33, for a total value of $3,783,951.15. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Kimberly Gentile sold 12,500 shares of Biohaven Pharmaceutical stock in a transaction dated Friday, June 15th. The stock was sold at an average price of $40.02, for a total value of $500,250.00. Following the completion of the transaction, the vice president now owns 12,500 shares in the company, valued at $500,250. The disclosure for this sale can be found here. Insiders sold 478,745 shares of company stock worth $16,350,046 over the last quarter. 34.20% of the stock is currently owned by corporate insiders.
Biohaven Pharmaceutical stock opened at $40.38 on Friday. The stock has a market capitalization of $1.56 billion and a PE ratio of -8.08. Biohaven Pharmaceutical Holding Co Ltd has a 52 week low of $16.50 and a 52 week high of $44.28.
Biohaven Pharmaceutical (NYSE:BHVN) last posted its quarterly earnings data on Tuesday, May 15th. The company reported ($2.32) EPS for the quarter, missing analysts’ consensus estimates of ($1.12) by ($1.20). research analysts predict that Biohaven Pharmaceutical Holding Co Ltd will post -6.33 EPS for the current fiscal year.
BHVN has been the topic of several recent research reports. Canaccord Genuity restated a “buy” rating and set a $34.00 target price (down from $39.00) on shares of Biohaven Pharmaceutical in a report on Monday, March 26th. Barclays lowered Biohaven Pharmaceutical from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $30.00 to $25.00 in a report on Thursday, April 5th. Zacks Investment Research upgraded Biohaven Pharmaceutical from a “hold” rating to a “buy” rating and set a $33.00 target price on the stock in a report on Friday, March 9th. Piper Jaffray Companies restated a “buy” rating on shares of Biohaven Pharmaceutical in a report on Monday, March 26th. Finally, Needham & Company LLC restated a “buy” rating and set a $36.00 target price on shares of Biohaven Pharmaceutical in a report on Wednesday, May 16th. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the stock. Biohaven Pharmaceutical presently has a consensus rating of “Buy” and an average price target of $39.57.
Biohaven Pharmaceutical Company Profile
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. Its lead product candidate is rimegepant, which is in Phase III clinical trials for the acute treatment of migraine. The company also develops trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia; and Phase II/III clinical trial for the treatment of obsessive compulsive disorders, as well as for the treatment of Alzheimer's diseases.
Want to see what other hedge funds are holding BHVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN).
Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.